GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Meda AB (STO:MEDAA):
The Nomination Committee of Meda AB proposes the election of Guido Oelkers and Martin Svalstedt as new board members and proposes the appointment of Martin Svalstedt as Board Chairman. The committee further proposes the re-election of Peter Claesson, Peter von Ehrenheim, Marianne Hamilton, Tuve Johannesson, Karen Sörensen and Lars Westerberg. Former CEO and board member Anders Lönner stepped down from the board when he stepped down from the position of CEO, and current Board Chairman Bert Åke Eriksson has declined re-election to the board.
Guido Oelkers is currently CEO of BSN Group, Hamburg. Oelkers has previous been CEO of Gambro AB and has experience from several global assignments. He holds a Ph.D. in strategic management.
Martin Svalstedt is currently CEO of Adactum AB, Stena sphere’s investment company, and is Board Chairman of Gunnebo AB and Ballingslöv AB. Svalstedt holds a Master of Science in Business Administration and Economics.
The nomination committee for the AGM 2014 consists of Evert Carlsson (Swedbank Robur Funds), Lars Backsell (B&E Participation AB), Anders Oscarsson (AMF Funds), Bert Åke Eriksson (Meda’s Chairman of the Board) and Karl-Magnus Sjölin (Stena Sessan).
The nomination committee's other proposals concerning the chairman of the meeting, remuneration and the method used to appoint the nomination committee will be disclosed on the website and in the notice of the Annual General Meeting.
The Annual General Meeting of Meda AB will be held on May 7, 2014 at 17.00 CET at Meda AB, Pipers väg 2A, Solna, Sweden.
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
This information was brought to you by Cision http://news.cision.com